LAGUNA HILLS, CA–(Marketwired – Aug 12, 2014) – Itonis, Inc. (PINKSHEETS: ITNS)
Itonis is very excited to announce that the procurement of raw materials for its first production run of Emesyl® is over 90% complete according to its manufacturer, Oasis Health Products.
The actual manufacturing of the company’s Emesyl® product is on schedule to begin August 18, 2014. We are pleased to be able to make these dates available to our shareholders. The completion and release of final product, including Quality Control testing will be September 12, 2014.
“We have been working very closely with Oasis and are pleased that the required lead times to procure packaging and raw product materials have been accurate, ensuring confidence that our timelines are met. We’re fully confident of the final product release date of September 12, and heavy focus is now in place on getting solid distribution orders. It won’t be long before Emesyl® will be available for retail purchase,” said Dr. Charles B. Hensley, the inventor of Emesyl® and the Zicam® Cold Remedy.
We are looking forward to these dates being met and distribution to begin for our flagship product Emesyl®, and will be updating shareholders with more information soon.
About Itonis Pharmaceuticals
Itonis Pharmaceuticals, a division of Itonis, Inc., is headed by Charles Hensley, Ph.D., and its mission is to create and market over-the-counter and prescription homeopathic products that better people’s lives. Dr. Hensley is a pioneer in the development and marketing of safe and effective therapeutic nutraceutical and homeopathic preparations. He was a founder of the company that launched the Zicam® Cold Remedy, making the product a household name and forever changing the marketing and product placement paradigm for homeopathic drugs in the United States. Dr. Hensley and his team plan to use the same methodologies to revolutionize the treatment of several other common ailments and other chronic diseases.
About Itonis, Inc.
Located in Laguna Hills, California, and founded in 2005, Itonis Inc. has focused on transitioning itself in the past year from acquiring high growth, market niche entrepreneurial companies, to a market leader focused on the distribution of innovative products to the medical and pharmaceutical industry. Please visit www.itonisholdings.com.
Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company’s future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company’s affiliates that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company’s filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.